Black women get screened most and still die most, in 37 of 40 states
The Commonwealth Fund's 2026 State Health Disparities Report, released in April 2026, found that in 37 of the 40 states with usable data, Black women had the highest breast cancer death rate, even though they got mammograms at high rates. The report ties the pattern to delays in follow-up testing after an abnormal mammogram and to cancers caught at later stages. It also notes that follow-up imaging and biopsies weren't historically free, and that under updated preventive guidelines, plans now must cover necessary follow-up imaging or pathology at no cost.
The screening numbers back this up. In 2022, Black women aged 50 to 74 reported the highest mammography use of any group, with 82.9 percent screened in the previous two years, and Black women aged 40 to 49 led their age band too, at 65.2 percent, according to a CDC Vital Signs analysis published in 2024. Black women are showing up for the test. The system is failing them after it.
That death rate isn't a story about more breast cancer. Black women don't have the highest breast cancer incidence of any group, yet their death rate is the highest even after accounting for age and stage at diagnosis, according to the USPSTF. The American Cancer Society's 2025 report finds that only 58 percent of Black women are diagnosed while the cancer is still localized.
In 2022 the American Cancer Society also reported that Black women have the lowest five-year relative survival of any racial or ethnic group at every stage of diagnosis and for every breast cancer subtype. Rebecca Siegel, the society's senior scientific director of cancer surveillance, put the responsibility where it belongs: "It is time for health systems to take a hard look at how they are caring differently for Black women."
In one study, Black women waited a median of five weeks from an abnormal mammogram to a diagnosis
An abnormal screening mammogram is not a diagnosis. It is a flag that something needs a closer look, usually a diagnostic mammogram or ultrasound, and sometimes a biopsy. The clock that matters for survival starts here, and each handoff after it is a place where care can stall.
A 2024 study in JCO Oncology Practice by Ritika Manik and colleagues tracked 2,554 women whose screening mammograms at an urban academic center came back abnormal. Black women waited a median of 12 days from the screen to diagnostic imaging and 21 more days from imaging to biopsy. Among those whose follow-up imaging looked suspicious, the median from screen to tissue diagnosis was 35 days.
Only 62.6 percent of Black women's abnormal screens were followed by diagnostic imaging within 15 days. After the researchers adjusted for insurance type, neighborhood disadvantage and other factors, Black women's chance of imaging within 15 days was 68.0 percent, and the authors called for national guidelines on how quickly diagnostic follow-up should happen.
A 2023 study in the Journal of Breast Imaging by Sora Yoon and colleagues at Duke found that a same-day biopsy program cut the overall wait from diagnostic imaging to biopsy. For Black women, the change wasn't statistically significant: the average wait went from 11.5 days before the program to 9.0 days after. A fix that speeds up a system on average can still leave Black patients waiting.
Whatever brought you to this page, community health centers see patients regardless of insurance and charge on a sliding scale that is often $0. Our directory of free and charitable clinics lists centers by state. A same-day telehealth visit is self-pay and is not billed to Medicaid, so if you have Medicaid the clinic route will usually cost less. If you would rather see a clinician online today:
See a doctor online today.
- Same-day video visits from $34
- Price shown before you book
- No insurance needed
with Sesame Care
Affiliate link, we may earn a commission at no extra cost to you.
The delay continues into treatment. In a population-based study of 32,626 North Carolina patients with breast cancer, Katherine Reeder-Hayes of the UNC Lineberger Comprehensive Cancer Center and colleagues found that 15.0 percent of Black patients waited more than 60 days from diagnosis to their first treatment. The study opens with the stakes: "Treatment delays affect breast cancer survival and constitute poor-quality care."
A 2024 follow-up in the Journal of Clinical Oncology measured structural racism county by county. For Black patients, every 10-point rise on that index was tied to 25 percent higher odds of a treatment delay.
The insurance change: most private plans now cover the tests after an abnormal screen
For years, the Affordable Care Act's no-cost coverage stopped at the screening mammogram, so extra views, an ultrasound, an MRI or a biopsy were billed as diagnostic. A 2023 study of 230,845 commercially insured women found that those in plans built around copays or deductibles had fewer follow-up breast imaging procedures than those in plans built around coinsurance.
That changed when HRSA updated its Women's Preventive Services Guidelines, accepted December 20, 2024. For women at average risk, the guideline now says that if additional imaging (MRI, ultrasound or mammography) and pathology evaluation are indicated, "these services also are recommended to complete the screening process for malignancies." Non-grandfathered private plans, including employer plans, must cover recommended HRSA services with no cost sharing.
The requirement starts with each plan's first plan year beginning on or after December 20, 2025, one year after HRSA accepted the update, so for most plans it took effect in 2026. A plan whose year started in October 2025 picks it up at its October 2026 renewal.
Grandfathered plans, generally those created on or before March 23, 2010 and not changed in certain ways since, are exempt. "Average risk" leaves out women with a BRCA mutation, untested women whose parent, sibling or child carries one, other inherited cancer syndromes, a previously diagnosed high-risk breast lesion, or high-dose chest radiation between ages 10 and 30. The guideline doesn't address extra services for women at higher risk.
Medicare runs on its own rules: after the Part B deductible, you pay 20 percent of the Medicare-approved amount for a diagnostic mammogram. Medicaid benefits are set state by state within federal guidelines, so ask your Medicaid plan how it pays for follow-up imaging.
Some states go further than the federal rule, which matters for imaging it doesn't reach, like a workup for a lump you found yourself or extra screening for women at higher risk. Washington and Maine bar cost sharing for diagnostic breast exams, including for an abnormality found outside a screening, and for supplemental exams for women at increased risk. Washington's law covers non-grandfathered plans issued or renewed on or after January 1, 2024, Maine's dates to 2023, and both carve out plans paired with a health savings account.
Pennsylvania's Act 52 of 2025 requires no-cost diagnostic breast exams when an abnormality is seen or suspected, plus no-cost supplemental screening a doctor recommends, for women at average risk or higher. It reaches policies filed or renewed from late July 2026 on. These state laws cover insurance the state regulates, not self-funded employer plans, which federal law keeps outside state insurance rules.
Triple-negative disease raises the cost of every delay
Triple-negative breast cancer grows fast, lacks the hormone and HER2 targets that many drugs rely on, and carries one of the worst prognoses. In a study of US cancer registry data from 2010 to 2015, 21.2 percent of breast cancers in Black patients were triple-negative, the highest share of any group studied. The USPSTF puts the incidence at 24.2 cases per 100,000 Black women.
When an aggressive subtype makes up that big a share, the weeks lost to follow-up and treatment delays carry more weight, not less. For its 2024 decision to lower the screening start age to 40, the USPSTF commissioned race-specific models for Black women. Those models estimated that screening every other year from 40 instead of 50 averts 1.8 more breast cancer deaths for every 1,000 Black women screened.
How to get care, and how to keep your case from stalling
The screening is the easy part now. Protecting yourself means managing what happens after it. When a screen is abnormal, ask three questions in the room or on the phone: when is my diagnostic appointment, will this be billed as preventive or diagnostic, and who is tracking that I actually get the next step.
If a biopsy is ordered, get the date in writing and a contact for results. If a bill for follow-up imaging or pathology arrives anyway, ask your plan in writing to reprocess it as preventive care under HRSA's Women's Preventive Services Guidelines. If the plan says no, file an internal appeal within 180 days of the denial and ask for an external review if that fails.
Care from a clinician who takes your symptoms seriously and moves fast changes outcomes. You can find a Black OB-GYN, primary care doctor, or breast specialist in our directory. For more on the subtype that drives much of this gap, read our explainer on triple-negative breast cancer in Black women, and on why showing up for the screen still matters, see our piece on Tina Knowles, breast cancer, and Black women's screening.
Frequently asked questions
If Black women get screened the most, why do they still die from breast cancer the most? ▼
The gap is no longer mainly about getting the mammogram. Black women lead the country in screening rates, but the care after an abnormal result stalls: in one study, the median wait from screen to tissue diagnosis was 35 days, and only 58 percent of Black women are diagnosed while breast cancer is still localized. The Commonwealth Fund's 2026 report found Black women had the highest breast cancer death rate in 37 of 40 states despite high mammography rates.
Is a diagnostic mammogram free like a screening mammogram? ▼
It depends on why you need it and what coverage you have. Starting with plan years that begin in 2026, most private plans must cover the extra imaging and pathology that finish an abnormal screening with no cost sharing, as long as you're at average risk and the plan isn't grandfathered. Imaging for a lump you found yourself falls outside that rule, though Washington, Maine and Pennsylvania have passed laws requiring no-cost diagnostic breast exams on state-regulated plans.
On Medicare, a diagnostic mammogram costs 20 percent of the Medicare-approved amount after the Part B deductible, and Medicaid coverage is set state by state. If a follow-up bill looks wrong, ask your plan in writing to reprocess it as preventive care, and appeal if it says no.
How long should I wait after an abnormal mammogram to get follow-up? ▼
Treat it as time-sensitive. In a 2024 study, Black women waited a median of 12 days for diagnostic imaging after an abnormal screen and another 21 days from imaging to biopsy. Ask for the soonest available diagnostic appointment, get any biopsy date in writing, and confirm who is responsible for tracking your results so your case doesn't stall between departments.
What is triple-negative breast cancer and why does it matter for Black women? ▼
Triple-negative breast cancer lacks the estrogen, progesterone, and HER2 receptors that many targeted treatments rely on, so it's harder to treat and tends to grow faster. In US cancer registry data, 21.2 percent of breast cancers in Black patients were triple-negative, the highest share of any group studied. Because an aggressive subtype makes up that large a share, delays in diagnosis and treatment carry more consequence.
When did the screening guidelines change, and should Black women start earlier? ▼
In 2024 the U.S. Preventive Services Task Force lowered the recommended start age for biennial screening mammography to 40 for women at average risk. It commissioned models specific to Black women, which estimated that screening every other year from 40 instead of 50 averts 1.8 more breast cancer deaths per 1,000 Black women screened. Talk to your clinician about your personal risk and family history, which may warrant earlier or additional screening.
